October 2007 Oncology News International

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

In first-line, EGFR-mutated NSCLC, targeted therapies such as osimertinib or amivantamab plus lazertinib are recommended.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

Cemiplimab Continues to Show Benefit Vs Chemo in PD-L1 ≥50% NSCLC

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Tim Cortese

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

A 5-year follow-up of the phase 3 EMPOWER-Lung 1 showed the greatest survival benefits in patients with NSCLC who have a PD-L1 expression of 90% or more.

Cristiane Decat Bergerot, PhD

April 14th 2025

High-Dose Radiotherapy Boosts Survival Without Toxicity Increase in LS-SCLC

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Phase 3 data support using twice-daily high-dose thoracic radiotherapy plus concurrent chemotherapy as an alternative therapy for patients with LS-SCLC.

Russ Conroy

92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer

Phase 3 data support using twice-daily high-dose thoracic radiotherapy plus concurrent chemotherapy as an alternative therapy for patients with LS-SCLC.

Michelle Sosa;Deirdre McNicholas;Arbelina Bebla;Seth Emont;Zhun Cao;Manu Tyagi;Craig Lipkin;Sommer Gunia

April 19th 2025

3 Things You Should Know About Unresectable NSCLC

Related Content

ONCOLOGY Staff

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

In first-line, EGFR-mutated NSCLC, targeted therapies such as osimertinib or amivantamab plus lazertinib are recommended.

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

Cemiplimab Continues to Show Benefit Vs Chemo in PD-L1 ≥50% NSCLC

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Tim Cortese

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

A 5-year follow-up of the phase 3 EMPOWER-Lung 1 showed the greatest survival benefits in patients with NSCLC who have a PD-L1 expression of 90% or more.

Cristiane Decat Bergerot, PhD

April 14th 2025

High-Dose Radiotherapy Boosts Survival Without Toxicity Increase in LS-SCLC

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Russ Conroy